Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of LVOT Gradient and LA Strain with Cardiac Events in Pediatric HCM.

Pediatric cardiology·2026

Same author

Occult obstructive sleep apnea in survivors of Hodgkin lymphoma following radiation therapy: an atypical and under-recognized phenotype.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine·2026

Same author

Multimodality Approach to Coronary Ischemic Testing in Pediatric Patients: A Scientific Statement From the American Heart Association.

Journal of the American Heart Association·2026

Same author

Isolated Nonischemic Left Bundle Branch Block Resulting in Heart Failure in Hodgkin Lymphoma Survivors Post-Radiation.

JACC. Case reports·2025

Same author

Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council Perspective.

JACC. CardioOncology·2025

Same author

Carvedilol to Improve Cardiac Remodeling in Anthracycline-Exposed Childhood Cancer Survivors: Subgroup Analysis of COG ALTE1621.

JACC. CardioOncology·2024

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.

Ming Hui Chen¹

¹Department of Cardiology, Children's Hospital Boston, 300 Longwood Avenue, Boston, MA 02115, USA. minghui.chen@cardio.chboston.org

Current Cardiology Reports

|April 22, 2009

Summary

Targeted cancer therapies like tyrosine kinase inhibitors improve survival but can cause reversible heart problems. Early detection and management of cardiotoxicity are crucial for continuous treatment.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: Jun 23, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

Oncology
Cardiology
Pharmacology

Background:

Targeted anticancer agents, including monoclonal antibodies and tyrosine kinase inhibitors, have significantly improved patient survival in malignancies.
Despite their efficacy, these therapies can lead to significant cardiotoxicity, manifesting as heart failure, left ventricular dysfunction, hypertension, myocardial infarction, and thromboembolism.

Purpose of the Study:

To review the potential cardiovascular side effects associated with frequently used tyrosine kinase inhibitors.
To discuss the diagnosis and management of cardiotoxicity in patients undergoing targeted cancer therapy.

Main Methods:

Review of literature on targeted anticancer agents and their associated cardiovascular toxicities.
Analysis of clinical presentations, diagnostic approaches, and management strategies for cardiotoxicity.

Main Results:

Cardiotoxicity is a recognized complication of targeted anticancer therapies.
Cardiotoxic effects are often reversible and manageable with medical intervention.
Early identification of cardiovascular side effects is key to maintaining uninterrupted, life-prolonging therapy.

Conclusions:

Cardiovascular side effects are an important consideration in patients receiving targeted anticancer therapy.
Prompt diagnosis and appropriate medical management can mitigate cardiotoxicity, allowing for continued treatment.
Vigilance for and proactive management of cardiotoxicity are essential for optimizing outcomes in cancer patients.